Xuanzhubio-b

Status: Publicly traded

Direct answer

Xuanzhubio-b is publicly traded on HKSE under the ticker 2575.HK.

Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line...

Can you invest in Xuanzhubio-b?

Yes. Xuanzhubio-b is publicly traded on HKSE under the ticker 2575.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Xuanzhubio-b

Detailed equity research is provided by MarketSnap.